MAP2K7 and metabolic syndrome: The results of this study also point out that in a hyperlipidemia patient, chlorambucil/prednisolone chemotherapy may be a better option than tyrosine kinase inhibitors because these drugs may aggravate the dyslipidemia of the patient, which was revealed in the background study focused on the RAS-RAF-MEK pathway.